Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia
NCT04712851Phase 2Active, not recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jun 2021
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cervical intraepithelial neoplasia (CIN), cervical squamous cell carcinoma (CSCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Jun 2021; status: active, not recruiting.
02
Drugs
03
Conditions
cervical intraepithelial neoplasia (CIN)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NCT04712851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04712851.